Australia markets close in 2 hours 6 minutes
  • ALL ORDS

    7,749.70
    +3.80 (+0.05%)
     
  • ASX 200

    7,541.40
    +2.40 (+0.03%)
     
  • AUD/USD

    0.6921
    +0.0031 (+0.45%)
     
  • OIL

    74.92
    +0.81 (+1.09%)
     
  • GOLD

    1,887.60
    +8.10 (+0.43%)
     
  • BTC-AUD

    33,077.06
    -213.32 (-0.64%)
     
  • CMC Crypto 200

    525.13
    -0.01 (-0.00%)
     
  • AUD/EUR

    0.6441
    +0.0028 (+0.44%)
     
  • AUD/NZD

    1.0924
    +0.0006 (+0.06%)
     
  • NZX 50

    12,155.38
    -41.77 (-0.34%)
     
  • NASDAQ

    12,464.51
    -108.85 (-0.87%)
     
  • FTSE

    7,836.71
    -65.09 (-0.82%)
     
  • Dow Jones

    33,891.02
    -34.99 (-0.10%)
     
  • DAX

    15,345.91
    -130.52 (-0.84%)
     
  • Hang Seng

    21,497.44
    +275.28 (+1.30%)
     
  • NIKKEI 225

    27,754.36
    +60.71 (+0.22%)
     

Atreca to Present at Upcoming Investor Conferences

Atreca, Inc.
Atreca, Inc.

SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming conferences:

Cowen 6th Annual IO Next Summit
November 11, 2022
Fireside Chat: 2:40-3:00 am EST, November 11, 2022

Stifel Healthcare Conference
November 15-16, 2022
Fireside Chat: 8:00-8:30 am EST, November 15, 2022

Evercore ISI HealthCONx Conference
November 29 - December 1, 2022
Fireside Chat: 9:40-10:00 am EST, December 1, 2022

Live webcasts of the presentations can be accessed through the Events & Presentations section of the Company's website at http://ir.atreca.com. An archived replay of each presentation will be available on the Company's website for 30 days following the live broadcast.

About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101, a monoclonal antibody targeting a novel ribonucleoprotein complex, as well as ATRC-301, an antibody drug conjugate targeting a novel epitope on EphA2. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients, and ATRC-301 is in IND-enabling studies. For more information on Atreca, please visit www.atreca.com.

Forward-Looking Statements
This release contains statements regarding matters that are not historical facts that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our strategy and future plans, including statements regarding the development of ATRC-101, ATRC-301, and our preclinical and clinical plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251
agray@atreca.com

Media:
Julia Fuller, 858-692-2001
Julia@fordhutmanmedia.com